« Return to News | Ethics/Regulatory

Parliament committee adopts amendments to proposed clinical trial regulation

Monday, June 3, 2013 11:35 AM

The European Parliament’s Committee on Environment and Public Health has unanimously adopted reporter Glenis Willmott’s amendments to the Commission’s proposed regulation on clinical trials, including provisions requiring sponsors to publish full clinical study reports once a marketing authorization decision has been taken.

Under the proposals endorsed by the Environment Committee, every trial would have to be registered on a publicly accessible EU database and its main findings reported within a year of the study ending. Non-compliance with the transparency provisions would result in sponsors being fined.

Transparency campaigners such as the AllTrials initiative had been concerned about the lack of measures in the proposed regulation overhauling the Clinical Trials Directive to ensure comprehensive registration and reporting of trials of medicines currently in use.

Willmottt’s proposals only somewhat allay these concerns, though, as the transparency provisions would not apply retroactively.  

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.